Meeting Overview - The third meeting of the Supervisory Board of Jiangsu Aidi Pharmaceutical Co., Ltd. was held on June 27, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal to cancel part of the unvested restricted stock, stating that it complies with relevant laws and regulations, and does not harm shareholders' interests [1][2]. - The Supervisory Board approved the draft of the 2025 Stock Option Incentive Plan, which aligns with legal requirements and is expected to benefit the company's sustainable development [2][3]. - The Supervisory Board approved the implementation assessment management measures for the 2025 Stock Option Incentive Plan, ensuring smooth execution and alignment with the company's governance structure [3][4]. - The Supervisory Board verified the list of initial incentive objects for the 2025 Stock Option Incentive Plan, confirming their qualifications under relevant laws and regulations [4][5]. - The Supervisory Board approved changes to certain fundraising investment projects and amount adjustments, aimed at enhancing operational stability and profitability [5][6]. - The Supervisory Board agreed to nominate Tang Jieqing as a candidate for a non-employee representative supervisor, pending shareholder approval [6][7]. - The Supervisory Board elected current employee representative supervisor Pang Qiuchen as the chairman of the Supervisory Board, effective immediately [7].

Core Viewpoint - Jiangsu Aidi Pharmaceutical Co., Ltd. is adjusting its fundraising investment projects to enhance the efficiency of fund usage and expedite the development of advantageous projects, specifically by reallocating funds from the "Ustectidine New Indication Research Project" to the "Integrase Inhibitor Drug Research and Clinical Study Project" [4][8][14] Fundraising Investment Project Overview - As of June 20, 2025, the raw material drug production research and supporting facilities project has been completed, while other fundraising projects are ongoing [2] - The total amount of committed investment for the projects is 542.8 million yuan, with 396.6 million yuan invested by June 20, 2025 [3] Changes and Amount Adjustments - The company plans to change the name of the project "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" and adjust the investment amounts accordingly [4][5] - The remaining funds of 84.3699 million yuan from the original project will be fully allocated to the new project to meet its funding needs [6][9] Reasons for Changes - The original project faced delays due to stricter regulatory requirements and the need for further evaluations, prompting the company to reallocate funds to a project with more immediate needs [7][8] - The "Integrase Inhibitor Drug Research and Clinical Study Project" is crucial for the company's pipeline, aiming to develop a new generation of integrase inhibitors for HIV treatment [9][10] Impact of Changes - The adjustments are expected to improve the efficiency of fund usage and support the company's long-term development strategy without adversely affecting normal operations [12][14] - The project aims to enhance the effectiveness and safety of HIV treatments, aligning with national policy goals and expanding the company's product offerings [10][12] Approval Process - The board of directors and the supervisory board have approved the changes, which will be submitted for shareholder approval [13][14]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-032 江苏艾迪药业股份有限公司 关于开立募集资金临时补流专项账户并签署募集资 金临时补流专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"艾迪药业"或"公司"）于 2025 年 6 月 27 日召开了第三届董事会第四次会议，审议通过了《关于开立募集资金 临时补流专项账户并签署募集资金临时补流专户存储三方监管协议的议案》，现 将有关情况公告如下： 一、 募集资金基本情况 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首次 公开发行股票注册的批复》 （证监许可〔2020〕1185 号）核准，公司向社会公开 发行人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总额为 人民币 839,400,000.00 元，扣除承销费用和保荐费用合计含税金额 61,758,000.00 元，实际募集资金到账 777,642,000.00 元。本次股票发行累计发生发行费用含税 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-030 江苏艾迪药业股份有限公司 关于监事会主席辞任暨补选非职工代表监事、监事会 主席的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会主席辞任情况 江苏艾迪药业股份有限公司（以下简称"公司"）监事会于近日收到公司监 事及监事会主席何凤英女士提交的辞任报告，何凤英女士申请辞去公司第三届监 事会非职工代表监事职务，辞任后其将继续在公司任职。 何凤英女士的辞任将导致公司监事会人数低于法定最低要求，根据《中华人 民共和国公司法》《公司章程》相关规定，何凤英女士的辞任将自公司股东会选 举产生新任监事后生效。在股东会选举出新任监事之前，何凤英女士将继续履行 监事职责。 公司于 2025 年 6 月 27 日召开第三届监事会第四次会议，审议通过了《关于 选举公司监事会主席的议案》,全体监事一致同意选举现任职工代表监事庞秋晨 先生（简历详见附件）担任公司第三届监事会主席，任期自本次监事会审议通过 之日起至第三届监事会任期届满之日止。 三、关于提名非职工代表监 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-028 江苏艾迪药业股份有限公司 关于变更财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）董事会于 2025 年 6 月 27 日召开第三届董事会第四次会议，审议通过了《关于变更财务总监的议案》，现 将相关情况公告如下： 一、财务总监聘任情况 （以下简称" 《公司法》"）、 《江苏艾迪药业股 份有限公司公司章程》 （以下简称"《公司章程》"）等相关规定，经公司董事会提 名委员会资格审查通过，并经审计委员会全体委员同意，公司于 2025 年 6 月 27 日召开第三届董事会第四次会议，审议通过了《关于变更财务总监的议案》。公 司董事会同意聘任董事会秘书刘艳女士兼任公司财务总监职务，任期自本次董事 会审议通过之日起至第三届董事会任期届满之日止。刘艳女士的简历见附件。 刘艳女士具备相应的任职资格，能够胜任财务相关职责的工作，不存在《公 司法》规定的不能担任公司高级管理人员、财务负责人的情形，未受过中国证监 ...

Core Points - The candidate, Hu Wenyuan, has been nominated as an independent director for Jiangsu Aidi Pharmaceutical Co., Ltd. and confirms his qualifications and independence [1][4] - The candidate possesses over five years of relevant experience in biopharmaceutical research, law, economics, accounting, finance, and management [1] - The candidate meets the legal and regulatory requirements for independent directors as outlined by various Chinese laws and regulations [1] - The candidate declares independence and does not fall under any disqualifying conditions related to family ties, shareholding, or business relationships with the company [1][3] - The candidate has no adverse records in the last 36 months, including no administrative or criminal penalties from the China Securities Regulatory Commission [2][3] - The candidate has not been disqualified from serving as an independent director due to attendance issues in previous roles [3] - The candidate has participated in training and holds relevant certification recognized by the stock exchange [6] - The candidate commits to adhering to laws, regulations, and the rules of the Shanghai Stock Exchange while ensuring sufficient time and effort to fulfill his duties [4]

General Information - Jiangsu Aidea Pharmaceutical Co., Ltd. was established as a joint-stock company based on the transformation of a limited liability company, registered in Yangzhou, Jiangsu Province with a unified social credit code of 913210006979433664 [1] - The company was approved by the Shanghai Stock Exchange on June 1, 2020, and registered by the China Securities Regulatory Commission on June 18, 2020, issuing 60 million shares of RMB ordinary stock, and was listed on the Sci-Tech Innovation Board on July 20, 2020 [1][3] Company Structure - The registered capital of the company is RMB 420.782808 million [2] - The company is a permanent stock company, with all assets divided into equal shares, and shareholders are liable for the company's debts only to the extent of their subscribed shares [2][3] - The chairman of the board represents the company in executing its affairs and is the legal representative [2] Business Objectives and Scope - The company's business objective is to leverage the strengths of its joint venture partners to develop the biopharmaceutical business, providing high-quality products and creating economic and social benefits to return to shareholders and society [3] - The approved business scope includes drug research and development, production and sales, development and processing of effective components from animal organs and plant materials, and technology research and transfer [3][4] Share Issuance and Management - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1.00 [4] - The total number of shares issued by the company is 420.782808 million, all of which are ordinary shares [5] - The company cannot repurchase its own shares except under specific circumstances, such as dissenting shareholders requesting buybacks due to merger resolutions [7][8] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, participate in shareholder meetings, supervise company operations, and access company documents [11][12] - Shareholders holding more than 5% of voting shares must report any pledges of their shares to the company [15][16] - The company must ensure that shareholders do not abuse their rights to harm the company or other shareholders [15][16] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting occurring once a year [22] - Shareholders holding more than 10% of shares can request a temporary meeting [23] - The company must provide adequate notice and details about the meeting, including the agenda and voting procedures [27][28]

上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于江苏艾迪药业股份有限公司 作废 2022 年限制性股票激励计划部分已授予尚未归属的限 制性股票相关事项的 法律意见书 上海澄明则正律师事务所 上海市南京西路 1366 号恒隆广场二期 2805 室 电话：021-52526819 传真：021-52526089 www.cm-law.com.cn 上海澄明则正律师事务所 法律意见书 致：江苏艾迪药业股份有限公司 上海澄明则正律师事务所（以下简称"本所"）接受江苏艾迪药业股份有限公 司（以下简称"艾迪药业"或"公司"）的委托，担任公司2022年限制性股票激励计 划（以下简称"本次激励计划"）的特聘专项法律顾问。本所律师根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、 （以下简称"《管理办法》"）、 《上市公司股权激励管理办法》 《上海证券交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）及 《科创板上市公司自律监管指南第4号——股权激励信息披露》（以下简称"《自 律监管指南》"）等有关法律、法规和规范性文件的规定以及《江苏艾迪 ...

Core Viewpoint - The company, Jiangsu Aidi Pharmaceutical Co., Ltd., has proposed a stock option incentive plan aimed at attracting and retaining talent, aligning the interests of shareholders, the company, and its core team for long-term development [6][7]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting 11.375 million stock options, representing approximately 2.703% of the company's total share capital of 420,782,808 shares [2][11]. - The initial grant consists of 9.1 million options, accounting for 2.163% of the total share capital, while 2.275 million options are reserved [2][11]. Stock Option Details - The exercise price for the stock options is set at 13.01 yuan per share [4][17]. - The plan allows for adjustments to the number of options or exercise price in case of capital increases, stock dividends, or other corporate actions [3][27]. Eligible Participants - A total of 45 individuals will receive the initial stock options, representing 6.392% of the company's projected employee count of 704 by the end of 2024 [3][9]. - The plan excludes independent directors and supervisors from participation [4][10]. Plan Duration and Conditions - The incentive plan is valid for a maximum of 48 months from the date of the first grant [6][12]. - The plan includes specific performance targets for both company-level and individual-level assessments to determine the eligibility for exercising options [20][18]. Management and Approval Process - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [7][21]. - The plan must be publicly disclosed and approved by shareholders, requiring a two-thirds majority vote [22][23]. Performance Assessment - The performance assessment for the company includes revenue and net profit targets for the years 2025 and 2026, with specific thresholds for option exercise eligibility [20][18]. - Individual performance will also be evaluated, impacting the number of options that can be exercised [19][20]. Adjustments and Compliance - The plan includes provisions for adjusting stock options and exercise prices in response to corporate actions such as stock splits or dividends [27][26]. - The company commits to not providing financial assistance for exercising options, ensuring compliance with relevant laws and regulations [10][4].

Core Viewpoint - The company announced the cancellation of 1.504 million shares of unvested restricted stock from its 2023 stock incentive plan due to the departure of certain incentive targets and unmet performance criteria [6][7]. Group 1: Approval Process of the Stock Incentive Plan - The company held multiple board and supervisory meetings to approve the stock incentive plan and its related documents from August to September 2023 [1][2][3][4]. - Independent directors provided opinions on the incentive plan, and the supervisory board verified the relevant matters [2][4]. Group 2: Details of the Canceled Restricted Stock - A total of 126,000 shares were canceled due to three incentive targets leaving the company [6]. - The remaining shares were canceled because the company did not meet its performance targets for the fiscal years 2023 and 2024, with reported revenues of approximately 411.36 million yuan and 417.80 million yuan respectively [6]. - The HIV drug division also failed to meet its performance targets, with revenues of approximately 73.58 million yuan in 2023 and 149.90 million yuan in 2024 [6]. Group 3: Impact of the Canceled Restricted Stock - The cancellation of the restricted stock will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the ongoing implementation of the stock incentive plan [7]. Group 4: Supervisory Board and Legal Opinions - The supervisory board agreed that the cancellation of the restricted stock complies with relevant laws and regulations, and does not harm shareholder interests [7]. - Legal opinions confirmed that the cancellation aligns with the regulations governing stock incentives and necessary disclosure obligations [8].